title: Gonadotropin-releasing hormone enhances the calving rate of beef females administered norgestomet and alfaprostol for estrus synchronization.
abstract: One hundred fifty beef heifers and 403 beef cows suckling calves were administered norgestomet implants (8 d) and alfaprostol, a PGF2 alpha analogue, approximately 28 h before implant removal. Thirty hours after implant removal, females were administered either GnRH via injection, GnRH via implantation, or no GnRH. The dosage of GnRH was 250 micrograms, and implants prolong the induced LH surge. Ovulation response, incidence of short cycles, and calving rate were analyzed as a 2 x 2 x 3 completely randomized factorial design with female (heifers and cows), estrous cycles (with or without), and GnRH as the main effects. There were no interactions (P > .10), and because heifers and cows had responses that did not differ (P > .25), they were summarized together. Females with estrous cycles had a higher (P < .05) ovulation response, fewer (P < .01) short luteal phases, and a higher (P < .01) calving rate than females without estrous cycles. Gonadotropin-releasing hormone treatment increased the ovulation response (P < .01) and the calving rate (P < .05), and these responses were not affected (P > .10) by the method of GnRH administration. Based on these data, the increased ovulation response to GnRH may account for 29% of the increase in calving rate observed in the GnRH-treated females. In summary, in norgestomet- and alfaprostol-synchronized females, GnRH enhanced calving rate regardless of how it was administered. This increase was due to more than an increased ovulation rate.
authors.affiliation: Department of Animal Sciences, University of Illinois, Urbana 61801, USA.
authors.forename: E R
authors.initials: ER
authors.lastname: doValle
authors.forename: L C
authors.initials: LC
authors.lastname: Cruz
authors.forename: D J
authors.initials: DJ
authors.lastname: Kesler
mesh_terms: D000818:Animals; D002417:Cattle / Q000097:blood / Q000502:physiology*; D004343:Drug Implants; D004973:Estrus Synchronization / Q000187:drug effects* / Q000502:physiology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology*; D007273:Injections, Intramuscular / Q000662:veterinary; D008183:Luteal Phase / Q000502:physiology; D007986:Luteinizing Hormone / Q000097:blood; D010060:Ovulation / Q000502:physiology; D011247:Pregnancy; D018873:Pregnancy Rate; D011282:Pregnenediones / Q000008:administration & dosage / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology*; D011460:Prostaglandins F / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation
chemical_list: D004343:Drug Implants; D011282:Pregnenediones; D045167:Progesterone Congeners; D011460:Prostaglandins F; D007987:Gonadotropin-Releasing Hormone; C100284:norgestomet; C038354:alfaprostol; D007986:Luteinizing Hormone